Literature DB >> 11821400

Expression of Sorsby's fundus dystrophy mutations in human retinal pigment epithelial cells reduces matrix metalloproteinase inhibition and may promote angiogenesis.

Jian Hua Qi1, Quteba Ebrahem, Karen Yeow, Dylan R Edwards, Paul L Fox, Bela Anand-Apte.   

Abstract

Sorsby's fundus dystrophy (SFD) is an autosomal dominant degenerative disease of the macula caused by mutations in the tissue inhibitor of metalloproteinase-3 (TIMP-3) gene. Choroidal neovascularization is a hallmark of this disease, which closely resembles the exudative form of age-related macular degeneration. However, the mechanism by which TIMP-3 mutations induce the disease phenotype in SFD remains unknown. To address this question we established human retinal pigment epithelial cell lines expressing wild type or S156C (Ser(156) changed to cysteine) mutant TIMP-3. S156C TIMP-3 had reduced matrix metalloproteinase (MMP) inhibitory activity in retinal pigment epithelial cells and resulted in increased secretion and activation of gelatinase A and B. The conditioned medium from these cells induced angiogenesis in "in vivo" chick chorioallantoic membrane assays that could be reversed with recombinant wild type TIMP-3. Our data indicate that the choroidal neovascularization in SFD may be a result of increased MMP activity, which could lead to the stimulation of angiogenesis. These results also suggest the potential therapeutic use of TIMP-3 or synthetic MMP inhibitors in this disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11821400     DOI: 10.1074/jbc.M110870200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  The association between statin use and age related maculopathy.

Authors:  G McGwin; C Owsley; C A Curcio; R J Crain
Journal:  Br J Ophthalmol       Date:  2003-09       Impact factor: 4.638

2.  A novel TIMP3 mutation associated with a retinitis pigmentosa-like phenotype.

Authors:  Meghan J DeBenedictis; Yosef Gindzin; Enrico Glaab; Bela Anand-Apte
Journal:  Ophthalmic Genet       Date:  2020-07-27       Impact factor: 1.803

Review 3.  [Pseudoxanthoma elasticum].

Authors:  M S Ladewig; C Götting; C Szliska; P C Issa; H-M Helb; I Bedenicki; H P N Scholl; F G Holz
Journal:  Ophthalmologe       Date:  2006-06       Impact factor: 1.059

4.  Tissue inhibitor of metalloproteinase-3 (TIMP3) promotes endothelial apoptosis via a caspase-independent mechanism.

Authors:  Jian Hua Qi; Bela Anand-Apte
Journal:  Apoptosis       Date:  2015-04       Impact factor: 4.677

Review 5.  Sorsby fundus dystrophy: Insights from the past and looking to the future.

Authors:  Bela Anand-Apte; Jennifer R Chao; Ruchira Singh; Heidi Stöhr
Journal:  J Neurosci Res       Date:  2018-08-21       Impact factor: 4.164

6.  Transcriptome analysis and molecular signature of human retinal pigment epithelium.

Authors:  N V Strunnikova; A Maminishkis; J J Barb; F Wang; C Zhi; Y Sergeev; W Chen; A O Edwards; D Stambolian; G Abecasis; A Swaroop; P J Munson; S S Miller
Journal:  Hum Mol Genet       Date:  2010-04-01       Impact factor: 6.150

7.  S156C mutation in tissue inhibitor of metalloproteinases-3 induces increased angiogenesis.

Authors:  Jian Hua Qi; Ganying Dai; Philip Luthert; Shyam Chaurasia; Joe Hollyfield; Bernhard H F Weber; Heidi Stöhr; Bela Anand-Apte
Journal:  J Biol Chem       Date:  2009-05-28       Impact factor: 5.157

Review 8.  Looking into the future: Using induced pluripotent stem cells to build two and three dimensional ocular tissue for cell therapy and disease modeling.

Authors:  Min Jae Song; Kapil Bharti
Journal:  Brain Res       Date:  2015-12-17       Impact factor: 3.252

9.  Tissue inhibitor of metalloproteinases-3 peptides inhibit angiogenesis and choroidal neovascularization in mice.

Authors:  Jian Hua Qi; Quteba Ebrahem; Mariya Ali; Alecia Cutler; Brent Bell; Nicholas Prayson; Jonathan Sears; Vera Knauper; Gillian Murphy; Bela Anand-Apte
Journal:  PLoS One       Date:  2013-03-01       Impact factor: 3.240

Review 10.  Engineering of tissue inhibitor of metalloproteinases mutants as potential therapeutics.

Authors:  Hideaki Nagase; Keith Brew
Journal:  Arthritis Res       Date:  2002-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.